TY - JOUR
T1 - Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients
AU - Gangat, Naseema
AU - Patnaik, Mrinal M
AU - Begna, Kebede
AU - Kourelis, Taxiarchis
AU - Al-Kali, Aref
AU - Elliott, Michelle A.
AU - Hogan, William
AU - Letendre, Louis
AU - Litzow, Mark R
AU - Knudson, Ryan A.
AU - Ketterling, Rhett P.
AU - Hodnefield, Janice M.
AU - Hanson, Curtis A.
AU - Pardanani, Animesh D
AU - Tefferi, Ayalew
PY - 2015
Y1 - 2015
N2 - Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13% vs 10% (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P
AB - Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13% vs 10% (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P
UR - http://www.scopus.com/inward/record.url?scp=84953319355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953319355&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2015.08.022
DO - 10.1016/j.mayocp.2015.08.022
M3 - Article
C2 - 26546107
AN - SCOPUS:84953319355
SN - 0025-6196
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
ER -